Manulife (Manufacturers Life Insurance)
CHRS icon

Manulife (Manufacturers Life Insurance)’s Coherus Oncology CHRS Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47.4K Sell
28,066
-6,032
-18% -$10.7K ﹤0.01% 2746
2025
Q4 		$48.4K Buy
34,098
+629
+2% +$917 ﹤0.01% 2821
2025
Q3 		$54.9K Buy
+33,469
New +$37.2K ﹤0.01% 2873
2025
Q2 		– Sell
-37,848
Closed -$30.5K – 2924
2025
Q1 		$30.5K Sell
37,848
-55
-0.1% -$63 ﹤0.01% 2868
2024
Q4 		$52.3K Buy
+37,903
New +$42.5K ﹤0.01% 2933
2024
Q3 		– Sell
-44,645
Closed -$77.2K – 3005
2024
Q2 		$77.2K Buy
44,645
+6,399
+17% +$12.9K ﹤0.01% 2890
2024
Q1 		$91.4K Buy
38,246
+373
+1% +$918 ﹤0.01% 2795
2023
Q4 		$126K Hold
37,873
– – ﹤0.01% 2755
2023
Q3 		$142K Buy
37,873
+5,562
+17% +$25.7K ﹤0.01% 2702
2023
Q2 		$138K Buy
32,311
+2,990
+10% +$17.6K ﹤0.01% 2738
2023
Q1 		$201K Hold
29,321
– – ﹤0.01% 2569
2022
Q4 		$232K Sell
29,321
-144
-0.5% -$1.11K ﹤0.01% 2467
2022
Q3 		$283K Sell
29,465
-736
-2% -$7.45K ﹤0.01% 2342
2022
Q2 		$219K Buy
30,201
+2,995
+11% +$26K ﹤0.01% 2609
2022
Q1 		$351K Sell
27,206
-6,300
-19% -$80.1K ﹤0.01% 2407
2021
Q4 		$535 Sell
33,506
-649
-2% -$11.3K ﹤0.01% 2213
2021
Q3 		$549K Sell
34,155
-2,810
-8% -$41.2K ﹤0.01% 2219
2021
Q2 		$511K Buy
36,965
+3,009
+9% +$42.6K ﹤0.01% 2410
2021
Q1 		$496K Sell
33,956
-919
-3% -$15.6K ﹤0.01% 2283
2020
Q4 		$606K Buy
34,875
+885
+3% +$15.8K ﹤0.01% 2085
2020
Q3 		$623K Sell
33,990
-651
-2% -$12.1K ﹤0.01% 1881
2020
Q2 		$600K Sell
34,641
-5,347
-13% -$90.5K ﹤0.01% 1867
2020
Q1 		$649K Buy
39,988
+2,848
+8% +$52.6K ﹤0.01% 1707
2019
Q4 		$669K Sell
37,140
-1,236
-3% -$22.8K ﹤0.01% 1884
2019
Q3 		$786K Sell
38,376
-195
-0.5% -$3.9K ﹤0.01% 1764
2019
Q2 		$852K Buy
38,571
+4,052
+12% +$70.4K ﹤0.01% 1726
2019
Q1 		$471K Buy
34,519
+2,186
+7% +$29.2K ﹤0.01% 2124
2018
Q4 		$293K Sell
32,333
-2,157
-6% -$25K ﹤0.01% 2170
2018
Q3 		$569K Sell
34,490
-1,563
-4% -$27.7K ﹤0.01% 2186
2018
Q2 		$505K Buy
36,053
+4,704
+15% +$67.3K ﹤0.01% 2381
2018
Q1 		$347K Sell
31,349
-28
-0.1% -$306 ﹤0.01% 2605
2017
Q4 		$276K Buy
31,377
+697
+2% +$7.46K ﹤0.01% 2763
2017
Q3 		$409K Buy
30,680
+287
+0.9% +$3.8K ﹤0.01% 2411
2017
Q2 		$436K Buy
30,393
+6,327
+26% +$122K ﹤0.01% 2395
2017
Q1 		$509K Buy
24,066
+3,542
+17% +$87.1K ﹤0.01% 2166
2016
Q4 		$578K Sell
20,524
-123
-0.6% -$3.44K ﹤0.01% 2006
2016
Q3 		$553K Sell
20,647
-139
-0.7% -$3.79K ﹤0.01% 2016
2016
Q2 		$351K Buy
20,786
+4,489
+28% +$84.3K ﹤0.01% 2258
2016
Q1 		$314K Buy
16,297
+180
+1% +$2.95K ﹤0.01% 2283
2015
Q4 		$370 Buy
16,117
+174
+1% +$4.48K ﹤0.01% 2214
2015
Q3 		$320 Buy
15,943
+321
+2% +$9.77K ﹤0.01% 2286
2015
Q2 		$452 Buy
15,622
+11,170
+251% +$282K ﹤0.01% 2197
2015
Q1 		$136 Buy
+4,452
New +$115K ﹤0.01% 3017

Other funds holding CHRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s CHRS Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its Coherus Oncology (CHRS) stake by 18% in Q1 2026, selling an estimated $10.7K and leaving 28,066 shares worth $47.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2746.

Manulife (Manufacturers Life Insurance) first reported a position in CHRS in Q1 2015 and has held it in 43 quarters since. The position peaked at $852K in Q2 2019. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Manulife (Manufacturers Life Insurance) held 28,066 shares of Coherus Oncology worth $47.4K as of Q1 2026.
  • Manulife (Manufacturers Life Insurance) sold 6,032 Coherus Oncology shares in Q1 2026, an estimated $10.7K.
  • Coherus Oncology made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #2746 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in Coherus Oncology in Q1 2015 and has held it in 43 quarters since.
  • Manulife (Manufacturers Life Insurance)'s Coherus Oncology position peaked at $852K in Q2 2019.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.